Instituto de Salud Pública de Navarra; Pamplona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP); Pamplona, Spain.
Hum Vaccin Immunother. 2013 May;9(5):1172-6. doi: 10.4161/hv.23451. Epub 2013 Jan 16.
Varicella vaccine effectiveness was evaluated in a case-control study in Navarre, Spain, in 2010-2012. The cases were 54 children aged 15 months to 10 years with a diagnosis of varicella confirmed by polymerase-chain-reaction. Each case was matched with eight controls by pediatric practice, district of residence and date of birth. The effectiveness was 87% (95% confidence interval: 60% to 97%) for one dose of vaccine and 97% (80% to 100%) for two doses. A single dose was 93% (34% to 100%) effective in the first year, which declined to 61% (95% CI: -64% to 94%) after the third year. In conclusion, varicella vaccine is highly effective in preventing confirmed cases, although this effect declines over time since the first dose. A second dose helps to reestablish very high levels of effectiveness and to reduce the risk of breakthrough varicella.
在西班牙纳瓦拉 2010-2012 年进行的一项病例对照研究中,评估了水痘疫苗的有效性。病例为 54 名年龄在 15 个月至 10 岁之间的儿童,其水痘诊断通过聚合酶链反应得到确认。每个病例均通过儿科实践、居住地区和出生日期与 8 名对照相匹配。一剂疫苗的有效性为 87%(95%置信区间:60%至 97%),两剂疫苗的有效性为 97%(80%至 100%)。一剂疫苗在第一年的有效性为 93%(34%至 100%),但在第三年后下降至 61%(95%CI:-64%至 94%)。总之,水痘疫苗在预防确诊病例方面非常有效,尽管自第一剂以来,这种效果会随时间推移而下降。第二剂有助于重新建立非常高的有效性,并降低突破性水痘的风险。